AWT020: a novel fusion protein harnessing PD-1 blockade and selective IL-2 Cis-activation for enhanced anti-tumor immunity and diminished toxicity
The AWT020 fusion protein offers a promising novel immunotherapeutic strategy by integrating PD-1 blockade and IL-2 signaling, conferring enhanced anti-tumor activity with reduced toxicity.
Authors
- Wen-Chin Huang (ORCID: https://orcid.org/0000-0003-3172-3335)
- Ella Li (ORCID: https://orcid.org/0009-0005-7265-5553)
- Yanghua Xu
- Jenny Jiang (ORCID: https://orcid.org/0000-0003-0341-1385)
- Ziyang Zhong (ORCID: https://orcid.org/0009-0006-4206-5728)
- Hanna Lin
- Jianing Huang (ORCID: https://orcid.org/0009-0000-3336-225X)
- Fan Ye (ORCID: https://orcid.org/0000-0002-1089-1498)
- Xiaoli Cheng
- Botong Hua
- Matthew Siegel
- Eugene Liu (ORCID: https://orcid.org/0000-0003-0211-8275)
- Binfeng Lu
- Bella Yue
- Eric C. Liao (ORCID: https://orcid.org/0000-0001-6385-7448)
- Xin Wang (ORCID: https://orcid.org/0000-0002-3529-5780)
- Honglin He (ORCID: https://orcid.org/0000-0002-8304-7239)
- Ji Wang (ORCID: https://orcid.org/0000-0002-2657-9132)
- Yuyuan Yan
- Wenli Shi (ORCID: https://orcid.org/0000-0001-5236-2781)
- Jiaming Wang (ORCID: https://orcid.org/0000-0001-7881-7158)
- Fang Huang
- Shih Chieh Chen
Institutions
- Hackensack Meridian Health (US)
- Center for Discovery (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-02-18
- DOI
- https://doi.org/10.3389/fimmu.2025.1537466
- Citations
- 6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 6.27